The ubiquitous yeast can also be found as resident members of the microbial flora of man and animals. The normal human microflora includes several genera of yeast, but the genus Candida is likely most important, Candida species can be isolated from the skin, oral cavity, and the genitourinary, alimentary, and respiratory tracts of most individuals. Although they are typically considered harmless commensals, yeasts are also important in human disease. Some species are called "opportunistic pathogens" because they can take advantage of specific opportunities (i.e., clinical conditions) to cause disease. These clinical conditions include immunosuppression, as well as antibiotic-induced elimination of competing bacterial flora. The elimination of microbial competition facilitates overgrowth of Candida species normally present in low numbers.
It should be emphasized that even though Candida species are found in the normal microbial flora of essentially all individuals, some have proposed that asymptomatic colonization with Candida is associated with a disease termed either Candida Hypersensitivity Syndrome, or Candida-Related Complex, or Polysystemic Candidiasis, or Chronic Candidiasis. This syndrome is allegedly associated with broad-spectrum antibiotic therapy, oral contraceptives, diets rich in yeast, and pregnancy. Although there are numerous uncritical publications on this topic.no peer-reviewed data in major journals confirm the existence of this syndrome, even though brief communications (that lack peer-reviewed data) have appeared in major journals. Recommended therapies for this syndrome include long-term administration of antifungal drugs, elimination of yeast from the diet, and Candida allergy shots. There are no data published in peer-reviewed journals verifying that these therapies are effective. A clear and factual explanation of this topic can be obtained at the website in reference 4. This website is dedicated to providing a wide range of scholarly peer-reviewed contemporary and historical information regarding fungi. The general goal of the website is to promote an understanding of fungi and the ways fungal diseases of humans, animals, and plants affect people throughout the world. The editorial board includes some of the most highly respected mycologists in the scientific community.
In clinical medicine, Candida species can cause a spectrum of diseases ranging from superficial infections (such as skin infections, oral infections, and vaginitis) to systemic life threatening systemic infections that involve the blood stream, liver, spleen, kidneys, etc. The Candida species most frequently associated with human disease include C alhicans, C. tropicalis, C. pampsilosis, and C. glabrata. Candida species are currently the fourth most common cause of nosocomial (hospital acquired) blood stream infection. These systemic infections are life threatening. Despite appropriate antifungal therapy, associated mortality is high and ranges from 38% to 75%. Patients at highest risk for systemic candidiasis include neonates, diabetics, and AIDS patients, but most cases occur in immunosuppressed patients, trauma patients, and postsurgical patients. A large proportion of cases occur in intensive care units. Risk factors include decreased numbers of white blood cells, prolonged physiologic support, vascular catheters, broad spectrum antibiotics, parenteral nutrition, hemodiah/sis, mucosal coloniza- tion, abdominal surgery, damage to the gastrointestinal tract, burns, and corticosteroids. Other risk factors associated with mortality include age, renal failure, hepatic failure, postoperative shock, and respiratory disease syndrome. Due to the high mortality associated with systemic disease caused by Candida species, coupled with the ineffectiveness of available antifungal therapy, many researchers are studying the mechanisms by which this typically harmless commensal fungus causes systemic disease. Here, the long-term goal is to identify therapies to interfere with disease initiation in high risk patients.
Thus, in a variety of settings (industrial, agricultural, biomedical), the ability to assess yeast viability is of great importance. Classical microbiological techniques of colony counting are cumbersome and time-consuming and may not accurately detect slowgrowing or non-dividing yeast. Molecular Probes, Inc. (Eugene, OR) has developed a family of fluorogenic probes that produce differential staining patterns in live and dead yeast cells. This family of fluorochromes is exemplified by the FUN-1 [2-chloro-4-(2,3-dihydro-3-methyI-(benzo-l J 3-thiazol-2-yl)-methylidene)-lphenylquinolinmm iodide] stain, which appears to work well with all genera and species of yeast tested to date. Molecular Probes LIVE/DEAD' Yeast Viability Kit combines the FUN-1 stain with Calcofluor White, an ultra-violet excitable dye that has long been used by mycologists as a marker of fungal cell walls. Using this kit, scientists should be able to easily distinguish, often in less than 30 minutes, live and dead fungal cells in a wide variety of industrial, agricultural, and biomedical samples. D riving the success of GlaxoSmithKline -the world's leading pharmaceutical organization -ife a continual search for innovation. Apart from a research and development capability that sets tile / benchmark for our industry, we're committed to recruiting and retaining the best and brightest by j providing unequaled individual and career development opportunities within our organization. Our mission is clear -to prevent, treat and cure,' diseases, allowing people around the world to ,00 more, feel better and live longer. We currently have/.--opportunities available in our state-of-the-art facility, located in Research Triangle" Park, NC.
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